Today, we announced a collaboration with @MDAndersonNews to develop a novel #microbiome treatment for individuals with immunotherapy-resistant #cancer.
Read today’s press release at prn.to/3kUl9id.
Today, we administered the first dose of our investigational bacterial cell therapy, FB-001. This Phase 1 #clinicaltrial will evaluate the safety, efficacy and engraftment of FB-001 in the treatment of enteric #hyperoxaluria, a serious metabolic disorder.
prn.to/3FBXqeF
Replying to @SFBusinessTimes
@SFBusinessTimes highlighted our CEO @edrabantconley
calling her a "multihyphenate scientist-wife-CEO-mom." On #IWD2021, we are proud to celebrate all of the “multihyphenate” women @FederationBio and in the #LifeSciences
#HealthThroughDiversity
https://teapawt.net/t.co/nX2D3pnSD3
An emerging scientific understanding of the human #microbiome is transforming our relationship with microbes – elevating them from menace to medicine as our understanding of their profound role in human physiology has come into focus. Learn more at Federation.bio
Emerging scientific understanding of the human #microbiome has demonstrated the profound role that microbes play in human physiology and rapidly elevated their therapeutic potential. Learn more about our novel approach at Federation.bio
We’re pioneering new approaches for treating intractable diseases by combining an unprecedented number of #microbial strains into highly diverse consortia, in some instances optimized with genetically engineered bacteria to enhance the immune system. Federation.bio
We’re pleased to announce that Federation Bio has come out of stealth mode with a $50 million Series A financing, two novel #microbial therapeutic platforms and an exceptional leadership team. Watch to see what we do next! Read the press release here: prn.to/34wujFF







